Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Efficacy and safety of heterologous booster vaccination with Ad26.COV2.S after BNT162b2 mRNA COVID‐19 vaccine in haemato‐oncological patients with no antibody response
Patrick Reimann, Hanno Ulmer, Beatrix Mutschlechner, et al.
British Journal of Haematology (2021) Vol. 196, Iss. 3, pp. 577-584
Open Access | Times Cited: 39

Showing 1-25 of 39 citing articles:

COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety
Annika Fendler, Elisabeth G.E. de Vries, Corine H. GeurtsvanKessel, et al.
Nature Reviews Clinical Oncology (2022) Vol. 19, Iss. 6, pp. 385-401
Open Access | Times Cited: 179
COVID-19 in patients with hematologic malignancy
Petra Langerbeins, Michael Hallek
Blood (2022) Vol. 140, Iss. 3, pp. 236-252
Open Access | Times Cited: 110
Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9)
Simone Cesaro, Per Ljungman, Małgorzata Mikulska, et al.
Leukemia (2022) Vol. 36, Iss. 6, pp. 1467-1480
Open Access | Times Cited: 107
SARS-CoV-2 in immunocompromised individuals
Susan DeWolf, Justin Laracy, Miguel‐Angel Perales, et al.
Immunity (2022) Vol. 55, Iss. 10, pp. 1779-1798
Open Access | Times Cited: 92
Vaccine schedule recommendations and updates for patients with hematologic malignancy post‐hematopoietic cell transplant or CAR T‐cell therapy
Gemma Reynolds, Victoria Hall, Benjamin W. Teh
Transplant Infectious Disease (2023) Vol. 25, Iss. S1
Open Access | Times Cited: 28
Current Progress, Challenges and Prospects in the Development of COVID-19 Vaccines
Congrui Zhu, Shengmei Pang, Jiaqi Liu, et al.
Drugs (2024) Vol. 84, Iss. 4, pp. 403-423
Closed Access | Times Cited: 10
Booster doses of COVID-19 vaccines for patients with haematological and solid cancer: a systematic review and individual patient data meta-analysis
Aaron Shengting, Ainsley Ryan Yan Bin Lee, Ryan Yong Kiat Tay, et al.
European Journal of Cancer (2022) Vol. 172, pp. 65-75
Open Access | Times Cited: 34
Antibody and T Cell Responses against SARS-CoV-2 Elicited by the Third Dose of BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) Vaccines Using a Homologous or Heterologous Booster Vaccination Strategy
Zsolt Matula, Márton Gönczi, Gabriella Bekő, et al.
Vaccines (2022) Vol. 10, Iss. 4, pp. 539-539
Open Access | Times Cited: 32
COVID-19 Vaccination in Patients With Cancer and Patients Receiving HSCT or CAR-T Therapy: Immune Response, Real-World Effectiveness, and Implications for the Future
Victoria Hall, Benjamin W. Teh
The Journal of Infectious Diseases (2023) Vol. 228, Iss. Supplement_1, pp. S55-S69
Open Access | Times Cited: 14
Immunity after COVID-19 Recovery and Vaccination: Similarities and Differences
Dorota Kamińska, Dominika Dęborska−Materkowska, Katarzyna Kościelska−Kasprzak, et al.
Vaccines (2022) Vol. 10, Iss. 7, pp. 1068-1068
Open Access | Times Cited: 22
Antibody response to a third booster dose of SARS-CoV-2 vaccination in adults with haematological and solid cancer: a systematic review
Youssra Al Hajji, Harriet Taylor, Thomas Starkey, et al.
British Journal of Cancer (2022) Vol. 127, Iss. 10, pp. 1827-1836
Open Access | Times Cited: 21
Immunogenicity of SARS-CoV-2 vaccines in patients with cancer
Helen Kakkassery, Esme Carpenter, Piers Patten, et al.
Trends in Molecular Medicine (2022) Vol. 28, Iss. 12, pp. 1082-1099
Open Access | Times Cited: 19
Efficacy of COVID-19 Booster Vaccines in Patients with Hematologic Malignancies: Experiences in a Real-World Scenario
Carolin Krekeler, Lea Reitnauer, Ulrike Bacher, et al.
Cancers (2022) Vol. 14, Iss. 22, pp. 5512-5512
Open Access | Times Cited: 18
Immunogenicity and risks associated with impaired immune responses following SARS-CoV-2 vaccination and booster in hematologic malignancy patients: an updated meta-analysis
Noppacharn Uaprasert, Palada Pitakkitnukun, Nuanrat Tangcheewinsirikul, et al.
Blood Cancer Journal (2022) Vol. 12, Iss. 12
Open Access | Times Cited: 17
Adult Patients with Cancer Have Impaired Humoral Responses to Complete and Booster COVID-19 Vaccination, Especially Those with Hematologic Cancer on Active Treatment: A Systematic Review and Meta-Analysis
Εfstathia Liatsou, Ioannis Ntanasis‐Stathopoulos, Stavros Lykos, et al.
Cancers (2023) Vol. 15, Iss. 8, pp. 2266-2266
Open Access | Times Cited: 10
COVID-19 vaccines: A comprehensive review of safety and efficacy
Zhipeng Yan, Ming Yang, Ching‐Lung Lai
Elsevier eBooks (2025), pp. 685-777
Closed Access
Safety of two-dose schedule of COVID-19 adsorbed inactivated vaccine (CoronaVac; Sinovac/Butantan) and heterologous additional doses of mRNA BNT162b2 (Pfizer/BioNTech) in immunocompromised and immunocompetent individuals
Karina Takesaki Miyaji, Karim Yaqub Ibrahim, Vanessa Infante, et al.
Revista do Instituto de Medicina Tropical de São Paulo (2025) Vol. 67
Open Access
Self‐Reported Adverse Events Following COVID‐19 Vaccination Among Medical Sciences Students After a Symptomatology Training Program: A Cross‐Sectional Study
Taraneh Tavanaei Tamanaei, Mohammad Bagher Oghazian, Mehran Mojtabaee, et al.
Health Science Reports (2025) Vol. 8, Iss. 3
Open Access
SARS‐CoV‐2 humoral responses following booster BNT162b2 vaccination in patients with B‐cell malignancies
Evangelos Terpos, Despina Fotiou, Vangelis Karalis, et al.
American Journal of Hematology (2022) Vol. 97, Iss. 10, pp. 1300-1308
Open Access | Times Cited: 16
The current status of COVID-19 vaccines. A scoping review
Manuel Rueda-Fernández, Lucia Melguizo‐Rodríguez, Víctor J. Costela‐Ruiz, et al.
Drug Discovery Today (2022) Vol. 27, Iss. 11, pp. 103336-103336
Open Access | Times Cited: 16
Anti-SARS-CoV-2 Antibody Testing: Role and Indications
Sylvia Mink, Peter Fraunberger
Journal of Clinical Medicine (2023) Vol. 12, Iss. 24, pp. 7575-7575
Open Access | Times Cited: 9
COVID-19 Vaccination Response and Its Practical Application in Patients With Chronic Lymphocytic Leukemia
Mazyar Shadman, Catherine Liu, Katherine Eakle, et al.
HemaSphere (2022) Vol. 7, Iss. 1, pp. e811-e811
Open Access | Times Cited: 12
Efficacy and safety of tixagevimab/cilgavimab as passive immunisation against COVID-19 infections in patients with hematological malignancies
Patrick Reimann, Verena Petzer, Axel Mündlein, et al.
Annals of Hematology (2024) Vol. 103, Iss. 6, pp. 2123-2131
Closed Access | Times Cited: 2
Interplay of inflammatory markers and anti-SARS-CoV-2 antibodies in COVID-19 mortality: A prospective cohort study
Sylvia Mink, Heinz Drexel, Andreas Leiherer, et al.
International Journal of Infectious Diseases (2024) Vol. 143, pp. 107016-107016
Open Access | Times Cited: 2
Antibody levels versus vaccination status in the outcome of older adults with COVID-19
Sylvia Mink, Christoph H. Saely, Andreas Leiherer, et al.
JCI Insight (2024) Vol. 9, Iss. 20
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top